Bright Minds Biosciences Inc. (DRUG) SEC Filings & Earnings Calls
EquiReason read 21 Bright Minds Biosciences Inc. SEC filings in the last 12 months. Latest: 6-K on 2026-10-02 — Report of voting results from annual general meeting; all director nominees elected and auditor appointed with overwhelming support..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 237.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Aug, in -68 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
2 Oct 20266-KReport of voting results from annual general meeting; all director nominees elected and auditor appointed with overwhelming support.open
Figures in the filing · each found in the filing text
| common shares voted · 2026-03-31 | 7,877,637 |
Risks flagged
No material risks identified; routine governance filing.
“All resolutions passed with overwhelming support; no dissent noted.”
1 Oct 20266-KBright Minds Biosciences filed a 6-K announcing participation in a research symposium and a corporate update on stock option rescission. No financial results or material business changes.open
Risks flagged
No material risk signals; option rescission is minor corporate housekeeping.
“Mutual rescission of 44,500 options; shares returned to treasury.”
17 Aug 20266-KQuarterly financial statements for a pre-revenue biotech; net loss increased, cash raised via equity offerings.open
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q3-2026 | $308M | |
| Net loss · Q3-2026 | $-20M | |
| Research and development expense · Q3-2026 | $28M | |
| Loss per share · Q3-2026 | $-2.26 |
Risks flagged
Pre-revenue biotech with increasing cash burn; reliance on equity financing for runway.
“Net loss $20.4M vs $8.1M; cash from financing $241.9M.”
2 Jul 2026SC 13D/ACEO Ian McDonald's beneficial ownership in Bright Minds Biosciences decreased to 13.6% due to share issuances, with no change in intent.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-07-02 | 13.6% |
2 Jul 2026SC 13D/ACEO Ian McDonald's beneficial ownership in Bright Minds Biosciences decreased to 13.6% due to share issuances, with no change in intent.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-07-02 | 13.6% |
28 May 20266-KStock options granted 109,000; Option exercise price $83.40open
Figures in the filing · each found in the filing text
| Stock options granted · point_in_time | 109,000 | |
| Option exercise price · point_in_time | $83.40 |
20 May 20266-KCash and cash equivalents $310M; Net loss $18M (+522% y/y); Research and development expenses $19M (+418% y/y)open
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $310M | |
| Net loss · H1-2026 | $18M | +522% y/y |
| Research and development expenses · H1-2026 | $19M | +419% y/y |
| Basic and diluted loss per share · H1-2026 | $2.08 | +373% y/y |
Risks flagged
Pre-revenue biotech with increasing R&D spend and no product revenue.
“No revenue reported; R&D expenses of $18.7M for H1-2026.”
13 Feb 20266-KBright Minds Biosciences files Q1 FY2026 financial statements: net loss of $7.6M, cash of $89M, R&D expenses $5.7M. No revenue or guidance.open
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-8M | |
| Research and development · Q1-2026 | $6M | |
| Cash and cash equivalents · Q1-2026 | $89M |
Risks flagged
Continued net losses and high R&D spending may lead to cash burn.
“Net loss of $7.6M and R&D expenses of $5.7M.”
9 Jan 20266-KBright Minds Biosciences closed a US$175M public offering of 1,945,000 common shares at US$90.00 per share, with proceeds for clinical trials and R&D.open
Figures in the filing · each found in the filing text
| Gross proceeds · Q1-2026 | $175M | |
| Shares offered · Q1-2026 | 1,945,000 | |
| Price per share · Q1-2026 | $90.00 |
Risks flagged
Dilution risk from new share issuance
“Issuance of 1,945,000 new common shares, representing significant dilution for existing shareholders.”
9 Jan 20266-KUnderwritten public offering of 1,945,000 common shares at $90.00 per share for gross proceeds of $175.05M. Net proceeds to fund clinical trials and R&D.open
Figures in the filing · each found in the filing text
| Gross proceeds · Q1-2026 | $175M | |
| Net proceeds · Q1-2026 | $164M | |
| Shares offered · Q1-2026 | 1,945,000 | |
| Price per share · Q1-2026 | $90.00 |
Risks flagged
Dilution risk from new share issuance
“Issuance of 1,945,000 new common shares, representing significant dilution for existing shareholders.”
8 Jan 20266-KBright Minds Biosciences announced pricing of an upsized US$175 million public offering of common stock at $90 per share. Also terminated its existing ATM program.open
Figures in the filing · each found in the filing text
| Gross proceeds · Q1-2026 | $175M | |
| Shares offered · Q1-2026 | 1,945,000 | |
| Price per share · Q1-2026 | $90.00 |
Risks flagged
Dilution risk from new share issuance
“Issuance of 1,945,000 new common shares, representing significant dilution for existing shareholders.”
7 Jan 20266-KBright Minds launches US$100M public offering of common shares and pre-funded warrants; dilutive event for existing shareholders.open
Figures in the filing · each found in the filing text
| gross proceeds | $100M |
Risks flagged
Dilution from offering may pressure existing shareholders.
“Offering of common shares and pre-funded warrants for US$100 million.”
7 Jan 20266-KBright Minds Biosciences mutually terminated its Equity Distribution Agreement with Piper Sandler and Cantor Fitzgerald, effective January 7, 2026.open
Risks flagged
Loss of equity distribution agreement may limit future capital raising flexibility.
“Termination of Equity Distribution Agreement with Piper Sandler and Cantor.”
6 Jan 20266-KBright Minds Biosciences announces positive Phase 2 topline results for BMB-101 in absence seizures and DEE: 73.1% median seizure reduction (p=0.012) and 63.3% reduction in major motor seizures; initiates global registrational trials.open
Figures in the filing · each found in the filing text
| Median reduction in absence seizures >=3s · Absence Seizure Cohort · Q1-2026 | 73.1% | |
| Median reduction in major motor seizures (DEE) · DEE Cohort · Q1-2026 | 63.3% | |
| Median reduction in total time in seizures (seizure burden) · Absence Seizure Cohort · Q1-2026 | 74.4% | |
| REM sleep increase · Absence Seizure Cohort · Q1-2026 | 90.0% | |
| Patients enrolled · Phase 2 BREAKTHROUGH · Q1-2026 | 24 |
Risks flagged
Phase 2 open-label design and small sample size (n=24) limit statistical power; discontinuations and missing data may affect reliability.
“Open-label, multicenter study; 3 patients discontinued in each cohort; one patient excluded due to baseline EEG not meeting criteria; one maintenance EEG insufficient quality.”
Regulatory and commercial risk: registrational trials still needed; no guarantee of FDA approval or market adoption.
“Company has initiated preparations for global registrational trials; no approved product yet.” · word for word
17 Nov 20256-KExpansion of Scientific Advisory Board with four PWS experts to support PWS program and BMB-105 clinical candidate. No financial or operational metrics.open
Risks flagged
Clinical trial risk: NOVA Phase 2a study may fail to meet endpoints, delaying or ending PWS program.
“The NOVA clinical study is a double-blind, randomized, Phase 2a study lasting up to 16 weeks... participants will be randomized in a 1:1 ratio to either BMB-101 or placebo.” · word for word
7 Nov 20256-KBright Minds Biosciences initiates Prader-Willi Syndrome program with Phase 2a study for BMB-101 and nominates BMB-105 as new clinical candidate. Positive pipeline expansion.open
Risks flagged
Clinical development risk; early-stage programs.
“Phase 2a study for PWS just initiated; top-line data for epilepsy expected early 2026.”
7 Nov 20256-KAnnouncement of conference presentations and grant of stock options; no material financial or operational event.open
Figures in the filing · each found in the filing text
| Stock options granted · 2025-10-30 | 43,000 | |
| Exercise price · 2025-10-30 | $54.47 |
Risks flagged
No material financial or operational update; limited investor relevance.
“Filing only contains conference presentation announcements and stock option grants.”
Bright Minds Biosciences Inc. — questions
- What did Bright Minds Biosciences Inc. file recently?
- 21 SEC filings in the last 12 months. Latest: 6-K on 2026-10-02 — Report of voting results from annual general meeting; all director nominees elected and auditor appointed with overwhelming support.
Every figure on this page comes from Bright Minds Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.